TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. 2007

Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
Human Gene Therapy Unit, Akdeniz University Faculty of Medicine, Antalya, Turkey

OBJECTIVE Tumor necrosis factor-related apoptosis inducing ligand (TRAIL) selectively induces apoptosis in cancer cells but not in normal cells, and a number of clinical trials have recently been initiated to test the safety and antitumoral potential of TRAIL in cancer patients. Four different receptors have been identified to interact with TRAIL: two are death-inducing receptors (TRAIL-R1 [DR4] and TRAIL-R2 [DR5]), whereas the other two (TRAIL-R3 [DcR1] and TRAIL-R4 [DcR2]) do not induce death upon ligation and are believed to counteract TRAIL-induced cytotoxicity. Because high levels of DcR2 expression have recently been correlated with carcinogenesis in the prostate and lung, this study investigated the importance of TRAIL and TRAIL receptor expression in breast cancer patients with invasive ductal carcinoma, taking various prognostic markers into consideration. METHODS Immunohistochemical analyses were performed on 90 breast cancer patients with invasive ductal carcinoma using TRAIL and TRAIL receptor-specific antibodies. Age, menopausal status, tumor size, lymph node status, tumor grade, lymphovascular invasion, perineural invasion, extracapsular tumor extension, presence of an extensive intraductal component, multicentricity, estrogen and progesterone receptor status, and CerbB2 expression levels were analyzed with respect to TRAIL/TRAIL receptor expression patterns. RESULTS The highest TRAIL receptor expressed in patients with invasive ductal carcinoma was DR4. Although progesterone receptor-positive patients exhibited lower DR5 expression, CerbB2-positive tissues displayed higher levels of both DR5 and TRAIL expressions. CONCLUSIONS DR4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D011980 Receptors, Progesterone Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives. Progesterone Receptors,Progestin Receptor,Progestin Receptors,Receptor, Progesterone,Receptors, Progestin,Progesterone Receptor,Receptor, Progestin
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
September 2014, Anticancer research,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
June 2008, Pathology oncology research : POR,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
August 2010, Archives of medical science : AMS,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
June 2014, Cancer biotherapy & radiopharmaceuticals,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
March 2007, The Medical journal of Malaysia,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
January 2013, Neoplasma,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
December 1985, Analytical and quantitative cytology and histology,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
December 2005, Journal of medical and dental sciences,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
January 2007, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Ahter D Sanlioglu, and Aylin F Korcum, and Elif Pestereli, and Gulgun Erdogan, and Seyda Karaveli, and Burhan Savas, and Thomas S Griffith, and Salih Sanlioglu
April 2013, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc,
Copied contents to your clipboard!